Dmitry I. Trukhan
Abstract
In 1984, Danish dermatologists described a skin eruption limited to the buttocks, with possible involvement of the intertriginous areas and flexion areas, and named this pattern the baboon syndrome. At the beginning of the 21st century, a new acronym SDRIFE (drug-associated symmetrical intertriginous and flexural exanthema) was proposed by Swiss dermatologists along with five characteristic diagnostic criteria. We searched the PubMed database for key terms: "baboon syndrome", "symmetrical drug-related intertriginous and flexural exanthema", "SDRIFE" from the time of the first publication (1984) to 04/30/2023. Found 120 descriptions of baboon syndrome or SDRIFE, which was slightly more common in men. An increase in the frequency of development with age was noted, 60% of cases were in patients older than 50 years. Geographically, more than half (52.4%) of cases are in Europe, predominantly in southern and western European countries, 20% in India and 16.2% in Asian countries. Attention is drawn to the variety of drugs that can cause the development of baboon/SDRIFE syndrome. Almost half – 59 cases (49.2%) of the 120 presented in the review are associated with antibiotics, 24 cases (20%) with antibiotics of the penicillin group. During the pandemic of a new coronavirus infection, SDRIFE cases have been described in patients with COVID-19 and after vaccination against COVID-19. The leading place in the diagnosis and treatment of SDRIFE belongs to the dermatologist. However, given the variety of culprit drugs, a doctor of any specialty can encounter SDRIFE in his practice.
Key words: baboon syndrome, drug-related symmetrical intertriginous and flexural exanthema, SDRIFE syndrome, drugs, culprit drugs, epidemiology
About the Author
Dmitry I. Trukhan 11 Omsk State Medical University, Omsk, Russia
References
1. Andersen KE, Hjorth N, Menné T. The baboon syndrome: systemicallyinduced allergic contact dermatitis. Contact Dermatitis 1984; 10 (2): 97–100. DOI: 10.1111/j.1600-0536.1984.tb00343.x
2. Häusermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis 2004; 51 (5–6): 297–310. DOI: 10.1111/j.0105-1873.2004.00445.x
3. Winnicki M, Shear NH. A systematic approach to systemic contact dermatitis and symmetric drug-related intertriginous and flexural exanthema (SDRIFE): a closer look at these conditions and an approach to intertriginous eruptions. Am J Clin Dermatol 2011; 12 (3): 171–80. DOI: 10.2165/11539080-000000000-00000
4. Cabrera Hernandez V, Gonzalez Afonso M, Callero Viera A, Martin-Fernandez Martin L. Symmetrical drug-related intertriginous and flexural exanthema due to clindamycin. BMJ Case Rep 2019; 12 (8): e230077. DOI: 10.1136/bcr-2019-230077
5. de Risi-Pugliese T, Barailler H, Hamelin A et al. Symmetrical drug-related intertriginous and flexural exanthema: A little-known drug allergy. J Allergy Clin Immunol Pract 2020; 8 (9): 3185–9.e4. DOI: 10.1016/j.jaip.2020.04.052
6. Wolf R, Tüzün Y. Baboon syndrome and toxic erythema of chemotherapy: Fold (intertriginous) dermatoses. Clin Dermatol 2015; 33 (4): 462–5. DOI: 10.1016/j.clindermatol.2015.04.008
7. Harbaoui S, Litaiem N. Symmetrical Drug-related Intertriginous and Flexural Exanthema.2022 Oct 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. URL: https://pubmed.ncbi. nlm.nih.gov/30969572/
8. Tan SC, Tan JW. Symmetrical drug-related intertriginous and flexural exanthema. Symmetrical drug-related intertriginous and flexural exanthema. Curr Opin Allergy Clin Immunol 2011; 11 (4): 313–8. DOI: 10.1097/ACI.0b013e3283489d5f
9. Muresan AM, Metze D, Böer-Auer A, Braun SA. Histopathological Spectrum and Immunophenotypic Characterization of Symmetrical Drug-Related Intertriginous and Flexural Exanthema. Am J Dermatopathol 2021; 43 (2): 103–11. DOI: 10.1097/DAD. 0000000000001722
10. Schuler AM, Smith EH, Chaudet KM et al. Symmetric drug-related intertriginous and flexural exanthema: Clinicopathologic study of 19 cases and review of literature. J Cutan Pathol 2021; 48 (12): 1471–9. DOI: 10.1111/cup.14090
11. Karadag AS, Ozlu E, Akdeniz N et al. Oral mucosal involvement and petechial lesions: a SDRIFE case with unusual findings. Cutan Ocul Toxicol 2016; 35 (2): 157–9. DOI: 10.3109/15569527.2015.1067227
12. Özkaya E, Babuna G. A challenging case: Symmetrical drug related intertriginous and flexural exanthem, fixed drug eruption, or both? Pediatr Dermatol 2011; 28 (6): 711–4. DOI: 10.1111/j.1525-1470. 2011.01656.x
13. Lima Miranda O, Martins J, Almeida A et al. Symmetrical Drug-related Intertriginous and Flexural Exanthema (Baboon Syndrome). Eur J Case Rep Intern Med 2021; 8 (12): 003029. DOI: 10.12890/ 2021_003029
14. Cancela-Díez B, López-Delgado D, Aneiros-Fernandez J, RuizVillaverde R. A Case of Intertriginous and Flexural Exanthema caused by Amoxicillin. Sultan Qaboos Univ Med J 2019; 19 (4): e369-e371. DOI: 10.18295/squmj.2019.19.04.014
15. Alpagat G, Baccioglu A, Dumanoglu B et al. Amoxicillin/Clavulanic Acid-Induced Symmetric Drug-Related Intertrigious and Flexural Exanthema. Cureus 2023; 15 (1): e33849. DOI: 10.7759/cureus.33849
16. Dogru M, Ozmen S, Ginis T et al. Symmetrical drug-related intertriginous and flexural exanthema (baboon syndrome) induced by amoxicillin-clavulanate. Pediatr Dermatol 2012; 29 (6): 770–1. DOI: 10.1111/j.1525-1470.2011.01577.x
17. Cox JAG. Symmetric, itching exanthema of the skin folds after penicillin use. Ned Tijdschr Geneeskd 2023 Jan 4; 167: D7005. URL: https://pubmed.ncbi.nlm.nih.gov/36633087/
18. Blackmur JP, Lammy S, Baring DE. Baboon syndrome: an unusual complication arising from antibiotic treatment of tonsillitis and review of the literature. BMJ Case Rep 2013; 2013: bcr2013201977. DOI: 10.1136/bcr-2013-201977
19. Handisurya A, Stingl G, Wöhrl S. SDRIFE (baboon syndrome) induced by penicillin. Clin Exp Dermatol 2009; 34 (3): 355–7. DOI: 10.1111/j.1365-2230.2008.02911.x
20. Chong WS, Lim HL. Symmetrical drug-related intertriginous and flexural exanthema (baboon syndrome) with fever induced by oral cloxacillin: does fever confound the diagnosis? J Dermatol 2010; 37 (9): 830–2. DOI: 10.1111/j.1346-8138.2010.00890.x
21. Heck J, Stichtenoth DO, Mettin R et al. Remdesivir-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE)? A case report with review of the literature. Eur J Clin Pharmacol 2021; 77 (1): 141–4. DOI: 10.1007/s00228-020-02955-4
22. Magnolo N, Metze D, Ständer S. Pustulobullous variant of SDRIFE (symmetrical drug-related intertriginous and flexural exanthema). J Dtsch Dermatol Ges 2017; 15 (6): 657–9. DOI: 10.1111/ddg.13031
23. Blanco Garcia-Granero D, Barranco R, García-Moguel I et al. First Case of Symmetric Drug-Related Intertriginous and Flexural Exanthema Induced by Meropenem. J Investig Allergol Clin Immunol 2021; 31 (6): 516-–7. DOI: 10.18176/jiaci.0685
24. Favrelière S, Hosteing S, Jazeron JF et al. A case of fixed drug eruption induced by doxycycline, mimicking a symmetrical drug-related intertriginous and flexural exanthema (SDRIFE). Therapie 2020t; 75 (5): 511–3. DOI: 10.1016/j.therap.2019.10.002
25. Li DG, Thomas C, Weintraub GS, Mostaghimi A. Symmetrical Drug-related Intertriginous and Flexural Exanthema Induced by Doxycycline. Cureus 2017; 9 (11): e1836. DOI: 10.7759/cureus.1836
26. Sahu K, Sirka CS, Pradhan S, Rout AN. Co-occurrence of Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) and Pigmented Fixed Drug Eruption (FDE) in a Single Patient Due to Doxycycline: A Case Report. Indian Dermatol Online J 2020; 11 (1): 62–4. DOI: 10.4103/idoj.IDOJ_104_19
27. Bumbacea RS, Ali S, Ogneva DO et al. Drug Provocation Testing in the Diagnosis of Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) Induced by Clarithromycin. Maedica (Bucur) 2021; 16 (2): 297–301. DOI: 10.26574/maedica.2020.16.2.297
28. Moreira C, Cruz MJ, Cunha AP, Azevedo F. Symmetrical drug-related intertriginous and flexural exanthema induced by clarithromycin. An Bras Dermatol 2017; 92 (4): 587–8. DOI: 10.1590/abd1806-4841. 20176125
29. Goossens C, Sass U, Song M. Baboon syndrome. Dermatology 1997; 194 (4): 421–2. DOI: 10.1159/000246167
30. Nespoulous L, Matei I, Charissoux A et al. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) associated with pristinamycin, secnidazole, and nefopam, with a review of the literature. Contact Dermatitis 2018; 79 (6): 378–80. DOI: 10.1111/cod. 13084
31. Tsai YW, Chung WH, Wang CW, Cheng CY. Levofloxacin-induced symmetric drug-related intertriginous and flexural exanthema. Contact Dermatitis 2022; 86 (1): 64–6. DOI: 10.1111/cod.13979
32. Megna M, Camela E, Ocampo Garza SS et al. Ciprofloxacin-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) in a psoriasis patient. Contact Dermatitis 2021; 85 (4): 467– 9. DOI: 10.1111/cod.13882
33. Kothari R, Mannu A, Vashisht D et al. Vancomycin Associated Purpuric Symmetrical Drug-Related Intertriginous and Flexural Exanthema: A Rare Association and an Uncommon Presentation. J Clin Pharmacol 2022; 62 (10): 1325–7. DOI: 10.1002/jcph.2069
34. Culav I, Ljubojevic S, Buzina DS. Baboon syndrome/SDRIFE due to sulfamethoxazole-trimethoprim. Int J Dermatol 2013; 52 (9): 1159–60. DOI: 10.1111/j.1365-4632.2011.05107.x
35. Şikar Aktürk A, Bayramgürler D, Salman S et al. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by oral metronidazole. Cutan Ocul Toxicol 2014; 33 (4): 337–8. DOI: 10.3109/15569527.2013.823981
36. Kumagai J, Nakamura A, Ogawa S, Washio K. Intravaginal metronidazole ovule-related allergic contact dermatitis. Contact Dermatitis 2021; 85 (1): 85–6. DOI: 10.1111/cod.13782
37. Zhang H, Xie Z. Symmetrical drug-related intertriginous and flexural exanthema induced by metronidazole suppository. Contact Dermatitis 2021; 84 (6): 486–8. DOI: 10.1111/cod.13780
38. Gulec AI, Uslu E, Başkan E et al. Baboon syndrome induced by ketoconazole. Cutan Ocul Toxicol 2014; 33 (4): 339–41. DOI: 10.3109/15569527.2013.870187
39. Kumar S, Bhale G, Brar BK. Symmetrical drug related intertriginous and flexural exanthema (SDRIFE) induced by fluconazole: An uncommon side effect of a commonly used drug. Dermatol Ther 2019; 32 (6): e13130. DOI: 10.1111/dth.13130
40. Mohapatra M, Panda M, Kar BR, Raj C. Symmetric Drug-related Intertriginous and Flexural Exanthema due to Itraconazole: An Uncommon Side Effect of a Commonly Used Drug. Indian Dermatol Online J 2017; 8 (6): 501–3. DOI: 10.4103/idoj.IDOJ_179_17
41. Hassanandani T, Panda M, Agarwal A, Das A. Rising trends of symmetrical drug related intertriginous and flexural exanthem due to Itraconazole in patients with superficial dermatophytosis: A case series of 12 patients from eastern part of India. Dermatol Ther 2020; 33 (6): e13911. DOI: 10.1111/dth.13911
42. Kalita BJ, Das S, Dutta B. Itraconazole-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): a rare occurrence. Int J Dermatol 2020; 59 (11): e419–e421. DOI: 10.1111/ijd.15049
43. Obara K, Maejima H, Katayama C et al. A case of symmetrical drug-related intertriginous and flexural exanthema induced by acetaminophen. J Dermatol 2014; 41 (12): 1132–3. DOI: 10.1111/1346-8138. 12666
44. Megna M, Cinelli E, Napolitano M et al. Paracetamol-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) in a psoriasis patient receiving apremilast therapy. Contact Dermatitis 2019; 81 (6): 451–4. DOI: 10.1111/cod.13358
45. Lugović-Mihić L, Duvančić T, Vučić M et al. SDRIFE (baboon syndrome) due to paracetamol: case report. Acta Dermatovenerol Croat 2013; 21 (2): 113–7. URL:https://pubmed.ncbi.nlm.nih.gov/ 24001419/
46. Erfan G, Yanik ME, Kaya S et al. Symmetrical drug-related intertriginous and flexural exanthema due to codeine. Indian J Dermatol Venereol Leprol 2015; 81 (4): 405–6. DOI: 10.4103/0378-6323.158665
47. Martins JF, Alen Coutinho I, Castro M et al. Remifentanil-Induced Symmetric Drug-Related Intertriginous and Flexural Exanthema: A Diagnostic Challenge in an Intensive Care Patient. J Investig Allergol Clin Immunol 2022; 32 (5): 399–401. DOI: 10.18176/jiaci.0764
48. Weiss D, Kinaciyan T. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by mefenamic acid. JAAD Case Rep 2018; 5 (1): 89–90. DOI: 10.1016/j.jdcr.2018.10.015
49. Kim BJ, Kim HS, Lee JY et al. Symmetrical drug-related intertriginous and flexural exanthema caused by celecoxib. Int J Dermatol 2014; 53 (1): e1-3. DOI: 10.1111/j.1365-4632.2011.05243.x
50. Ding R, Cheo FF, Lee HY. Celecoxib and Bullous Symmetrical Drug-Related Intertriginous and Flexural Exanthem (SDRIFE). J Allergy Clin Immunol Pract 2023; 11 (2): 629–31. DOI: 10.1016/j.jaip. 2022.11.028
51. Caralli ME, Seoane Rodríguez M, Rojas Pérez-Ezquerra P et al. Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) Caused by Etoricoxib. J Investig Allergol Clin Immunol 2016; 26 (2): 128–9. DOI: 10.18176/jiaci.0029
52. Watanabe T, Yamada N, Yoshida Y, Yamamoto O. A case of symmetrical drug-related intertriginous and flexural exanthema induced by loflazepate ethyl. J Eur Acad Dermatol Venereol 2010; 24 (3): 357–8. DOI: 10.1111/j.1468-3083.2009.03405.x
53. Suvarna P, Kayarkatte MN, Shenoi SD, Jaiprakash P. A rare case of clozapine-induced symmetrical drug-related intertriginous and flexural exanthema with vasculitis-like lesions. Contact Dermatitis 2020; 82 (5): 318–20. DOI: 10.1111/cod.13468
54. Rao A, Francis N, Morar N. Clozapine-induced symmetrical drug-related intertriginous and flexural exanthema: first reported cases. Br J Dermatol 2012; 166 (5): 1142–3. DOI: 10.1111/j.1365-2133.2011. 10758.x
55. Akkari H, Belhadjali H, Youssef M et al. Baboon syndrome induced by hydroxyzine.Indian J Dermatol 2013; 58 (3): 244. DOI: 10.4103/ 0019- 5154.110871
56. Allain-Veyrac G, Lebreton A, Collonnier C, Jolliet P. First case of symmetric drug-related intertriginous and flexural exanthema (SDRIFE) due to rivastigmine? Am J Clin Dermatol 2011; 12 (3): 210–3. DOI: 10.2165/11318350-000000000-00000
57. Akay BN, Sanli H. Symmetrical drug-related intertriginous and flexural exanthem due to oral risperidone. Pediatr Dermatol 2009; 26 (2): 214– 6. DOI: 10.1111/j.1525-1470.2009.00882.x
58. Treudler R, Simon JC. Symmetric, drug-related, intertriginous, and flexural exanthema in a patient with polyvalent intolerance to corticosteroids. J Allergy Clin Immunol 2006; 118 (4): 965–7. DOI: 10.1016/j.jaci.2006.07.023
59. Armingaud P, Martin L, Wierzbicka E, Esteve E. Baboon syndrome due to a polysensitization with corticosteroids. Ann Dermatol Venereol 2005; 132 (8–9 Pt. 1): 675–7. DOI: 10.1016/s0151-9638(05)79415-1
60. Garcia-Bravo B, Repiso JB, Camacho F. Systemic contact dermatitis due to deflazacort. Contact Dermatitis 2000; 43 (6): 359–60. DOI: 10.1034/j.1600-0536.2000.043006359.x
61. Virath R, Gupta LK, Balai M. A probable association of symmetrical drug-related intertriginous and flexural exanthema with levocetirizine. Indian J Dermatol Venereol Leprol 2020; 86 (6): 696–9. DOI: 10.4103/ijdvl.IJDVL_416_19
62. Yang SY, Lan CC, Hu SC. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by golimumab. Int J Dermatol 2017; 56 (5): 571–2. DOI: 10.1111/ijd.13565
63. Bulur I, Keseroglu HO, Saracoglu ZN, Gönül M. Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with infliximab. J Dermatol Case Rep 2015; 9 (1): 12–4. DOI: 10.3315/jdcr.2015.1190
64. Keshavamurthy C, Fibeger E, Virata A, Bansal P. Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with Infliximab: a case-based review. ARP Rheumatol 2022; 1 (4): 322–7. URL: https://pubmed.ncbi.nlm.nih.gov/36617314/
65. Göbel CH, Heinze A, Karstedt S et al. First Report of Symmetrical Drugrelated Intertriginous and Flexural Exanthema (SDRIFE or Baboon Syndrome) After Erenumab Application for Migraine Prevention. Pain Ther 2022; 11 (4): 1483–91. DOI: 10.1007/s40122-022-00417-6
66. Mofarrah R, Mofarrah R, Kränke B et al. First report of tamoxifen-induced baboon syndrome. J Cosmet Dermatol 2021; 20 (8): 2574–78. DOI: 10.1111/jocd.13863
67. Powers R, Gordon R, Roberts K, Kovach R. Symmetrical drug-related intertriginous and flexural exanthema secondary to topical 5-fluorouracil. Cutis 2012; 89 (5): 225-8. URL: https://pubmed.ncbi.nlm. nih.gov/22768435/#affiliation-1
68. Lewis W, Forrestel A, Baumrin E. Epidermal Growth Factor Receptor Inhibitor-Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent? Cutis 2023; 111 (1): 18–21. DOI: 10.12788/cutis.0681
69. Copps B, Lacroix JP, Sasseville D. Symmetrical drug-related intertriginous and flexural exanthema secondary to epidermal growth factor receptor inhibitor gefitinib. JAAD Case Rep 2020; 6 (3): 172–5. DOI: 10.1016/j.jdcr.2017.03.003
70. Keerty D, Graham L, Haynes E, Hembree TN. Flexural Exanthema From Enfortumab Vedotin. Cureus 2020; 12 (5): e8102. DOI: 10.7759/ cureus.8102
71. Malissen N, Bourrain J-L, Chiriac A et al. Symmetrical Intertriginous and Flexural Exanthema due to Bortezomib (a Proteasome Inhibitor) Given for Myeloma. Acta Derm Venereol 2016; 96: 995–6. DOI: 10.2340/00015555-241
72. Scherrer M, Araujo MG, Farah K. Tacrolimus-induced symmetric drugrelated intertriginous and flexural exanthema (SDRIFE). Contact Dermatitis 2018; 78 (6): 414–6. DOI: 10.1111/cod.12954
73. Kurtzman DJ, Oulton J, Erickson C, Curiel-Lewandrowski C. Everolimus-Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE). Dermatitis 2016; 27 (2): 76–7. DOI: 10.1097/DER.0000000000000164
74. Ferreira O, Mota A, Morais P et al. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by telmisartan-hydrochlorothiazide. Cutan Ocul Toxicol 2010; 29 (4): 293–5. DOI: 10.3109/15569527.2010.491103
75. Tchernev G, Oliveira N, Kandathil LJ. Baboon syndrome (SDRIFE) after valsartan/hydrochlorothiazide intake for several years. Dermatol Reports 2021; 14 (2): 9412. DOI: 10.4081/dr.2022.9412
76. Kardaun SH, Tupker RA. Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) induced by omeprazole. Int J Dermatol 2012; 51 (9): 1134–7. DOI: 10.1111/j.1365-4632.2010.04689.x
77. Kothari R, Pal R, Bhatnagar A et al. A rare case of symmetrical drug-related intertriginous and flexural exanthema due to pantoprazole. Int J Dermatol 2022; 61 (9): e330–e331. DOI: 10.1111/ijd.16155
78. Spigariolo CB, Barei F, Maronese CA, Barberi F, Cattaneo A, Violetti SA. Three cases of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by proton-pump inhibitors. Australas J Dermatol 2022; 63 (4): 509–12. DOI: 10.1111/ajd.13905
79. Binitha MP, Sasidharanpillai S, John R, Sherjeena PV. Symmetrical drug-related intertriginous and flexural exanthema due to ranitidine. Indian J Pharmacol 2014; 46 (5): 551-2. DOI: 10.4103/0253- 7613.140595
80. Seok J, Kim JM, Park KY, Seo SJ. Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Two Cases and Brief Literature Review. Ann Dermatol 2018; 30 (5): 606–9. DOI: 10.5021/ad.2018.30.5.606
81. Daito J, Hanada K, Katoh N et al. Symmetrical drug-related intertriginous and flexural exanthema caused by valacyclovir. Dermatology 2009; 218 (1): 60–2. DOI: 10.1159/000167829
82. Roche D, Murray G, Hackett C, Tobin AM. A flexural exanthem following postexposure prophylaxis. Clin Exp Dermatol 2022; 47 (6): 1204– 6. DOI: 10.1111/ced.15131
83. Heck J, Stichtenoth DO, Mettin R et al. Remdesivir-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE)? A case report with review of the literature. Eur J Clin Pharmacol 2021; 77 (1): 141–4. DOI: 10.1007/s00228-020-02955-4
84. Çakıcı ÖA, Güder S, Salman A, Ergun T. Symmetrical drug-related intertriginous and flexural exanthema-like eruption: An addition to the spectrum of coronavirus disease 2019-related cutaneous findings. Indian J Dermatol Venereol Leprol 2022; 88 (6): 814–6. DOI: 10.25259/IJDVL_165_2022
85. Kandala H, Gonzalez-Mosquera LF, Barua P, Podrumar A. Zoledronic acid-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE). BMJ Case Rep 2021; 14 (9): e245326. DOI: 10.1136/bcr-2021-245326
86. Cohen PR. Zoledronic acid-associated symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): report of baboon syndrome in a woman with recurrent metastatic breast cancer after receiving zoledronic acid. Dermatol Online J 2015; 21 (8): 13030/qt5kk0g864. URL: https://pubmed.ncbi.nlm.nih.gov/26437156/
87. Cheng CY, Wang CW, Wang FY, Chung WH. Varenicline-induced symmetrical drug-related intertriginous and flexural exanthema. Indian J Dermatol Venereol Leprol 2019; 85 (2): 209–11. DOI: 10.4103/ijdvl.IJDVL_768_17
88. Thierman S, Chinthraja RS. Symmetrical drug-related intertriginous and flexural exanthema after coronary artery angiography. J Hosp Med 2009; 4 (3): 203. DOI: 10.1002/jhm.420
89. Arnold AW, Hausermann P, Bach S, Bircher AJ. Recurrent flexural exanthema (SDRIFE or baboon syndrome) after administration of two different iodinated radio contrast media. Dermatology 2007; 214 (1): 89–93. DOI: 10.1159/000096920
90. Hattori Y, Matsuyama K, Shu E et al. Symmetrical drug-related intertriginous and flexural exanthema possibly due to thiamine disulfide. J Dermatol 2017; 44 (6): e115-e116. DOI: 10.1111/1346-8138.13776
91. Peeters D, Baeck M, Dewulf V et al. A case of SDRIFE induced by Nuvaring®. Contact Dermatitis 2012; 66 (2): 110–1. DOI: 10.1111/j.1600- 0536.2011.01990.x
92. Matos-Pires E, Pina-Trincão D, Brás S, Lobo L. Baboon syndrome caused by anti-haemorrhoidal ointment. Contact Dermatitis 2018; 78 (2): 170–1. DOI: 10.1111/cod.12880
93. Liu J, Li LF. Symmetrical drug-related intertriginous and flexural exanthema/baboon syndrome induced by traditional Chinese medicine. J Cosmet Dermatol 2022; 21 (5): 2200–4. DOI: 10.1111/jocd. 14343
94. Choi MJ, Oh SH, Cho SB. Coix lacryma-jobi associated symmetrical drug-related intertriginous and flexural exanthema. Int J Dermatol 2014; 53 (4): e301-3. DOI: 10.1111/ijd.12258
95. Labadie JG, Florek AG, Croitoru A et al. First case of symmetrical drugrelated intertriginous and flexural exanthema (SDRIFE) due to Berberine, an over-the-counter herbal glycemic control agent. Int J Dermatol 2018; 57 (9): e68-e70. DOI: 10.1111/ijd.14059
96. Chen B, Jiang X, Chen W et al. A rare case of musk antihemorrhoids ointment-induced symmetrical drug-related intertriginous and flexural exanthema. Contact Dermatitis 2020; 83 (5): 409–11. DOI: 10.1111/cod.1357
97. Mahé A, Birckel E, Krieger S et al. A distinctive skin rash associated with coronavirus disease 2019? J Eur Acad Dermatol Venereol 2020; 34 (6): e246–e247. DOI: 10.1111/jdv.16471
98. Escolà H, March-Rodriguez A, Pujol RM. Symmetrical drug-related intertriginous and flexural exanthema-like rash related to severe acute respiratory syndrome coronavirus 2 infection. Indian J Dermatol Venereol Leprol 2023; 89 (1): 119–21. DOI: 10.25259/IJDVL_355_2022
99. Chicharro P, Rodríguez-Jiménez P, Muñoz-Aceituno E et al. SDRIFElike rash associated with COVID-19, clinicopathological correlation. Australas J Dermatol 2021; 62: 88–9. DOI: 10.1111/ajd.13444
100. Bonamigo RR, Bottega GB, Staub FL et al. Bullous SDRIFE and Covid19. Int J Dermatol 2022; 6: 372–4. DOI: 10.1111/ijd.16012
101. Bevilaqua M, Ribolli GB, Luzzatto L et al. SDRIFE-like rash in COVID19 patient: drug reaction or another cutaneous manifestation of SARSCoV-2? Int J Dermatol 2021; 60: 884–5. DOI: 10.1111/ijd.15537
102. Bellinato F, Maurelli M, Gisondi P, Girolomoni G. Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines. J Clin Med 2021; 10 (22): 5344. DOI: 10.3390/jcm10225344
103. Manaa A, Ziv M, Krausz J, Dodiuk-Gad RP. A case of symmetrical drug-related intertriginous and flexural exanthema-like eruption associated with Pfizer COVID-19 vaccination. Dermatol Ther 2022; 35 (7): e15546. DOI: 10.1111/dth.15546
104. Lahouel I, Ben Salah N, Ben Fadhel N et al. Symmetrical drug-related intertriginous and flexural exanthema-like eruption after COVID-19 vaccine. J Eur Acad Dermatol Venereol 2022; 36 (8): e597–e599. DOI: 10.1111/jdv.18108
105. Hai J, Shawa H, Kim-Lim P et al. Systemic drug-related intertriginous and flexural exanthema induced by the Pfizer-BioNTech COVID-19 vaccine: A report of 2 cases. JAAD Case Rep 2021; 18: 57–60. DOI: 10.1016/j.jdcr.2021.10.016
106. Hong JK, Shin SH, Yoo KH et al. Symmetric drug-related intertriginous and flexural exanthema-like eruption related to coronavirus disease 2019 vaccine. Contact Dermatitis 2022; 87 (1): 91–3. DOI: 10.1111/cod.14092
107. Lim PN, Wylie G. Symmetrical drug-related intertriginous and flexural exanthema like eruption associated with COVID-19 vaccination. Clin Exp Dermatol 2022; 47 (1): 175–6. DOI: 10.1111/ced.14898
108. Di Bona D, Miniello A, Nettis E. Systemic drug-related intertriginous and flexural exanthema-like eruption after Oxford-AstraZeneca COVID-19 vaccine. Clin Mol Allergy 2022; 20 (1): 13. DOI: 10.1186/s12948-022-00179-8
109. Orenay OM, Balta I, Yigit D, Eksioglu M. Systemic drug-related intertriginous and flexural exanthema like eruption after CoronaVac vaccine. J Eur Acad Dermatol Venereol 2021; 35 (10): e634-e635. DOI: 10.1111/jdv.17454
110. Pottegård A, Hallas J, Olesen M et. al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 2017; 282 (4): 322–31. DOI: 10.1111/joim.12629
111. Pedersen SA, Gaist D, Schmidt SAJ et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol 2018; 78 (4): 673–81.e9. DOI: 10.1016/j.jaad.2017.11.042
112. Garrido PM, Borges-Costa J. Hydrochlorothiazide treatment and risk of non-melanoma skin cancer: Review of the literature. Rev Port Cardiol (Engl Ed) 2020; 39 (3): 163–70. DOI: 10.1016/j.repc.2019. 07.008
113. Lecaros-Astorga DA, Molina-Guarneros JA, Rodríguez-Jiménez P et al. Hydrochlorothiazide use and risk of non-melanoma skin cancer in Spain: A case/non-case study. Int J Clin Pharmacol Ther 2021; 59 (4): 280–8. DOI: 10.5414/CP203769
114. Becquart O, Guillot B, Bourrain J-L et al. Hydrochlorothiazide use and risk of skin cancers: A systematic review. Rev Med Interne 2019; 40 (9): 617–22. DOI: 10.1016/j.revmed.2019.04.008
114. Letellier T, Le Borgne F, Kerleau C et al; Divat Consortium. Association between Use of Hydrochlorothiazide and Risk of Keratinocyte Cancers in Kidney Transplant Recipients. Clin J Am Soc Nephrol 2020; 15 (12): 1804–13. DOI: 10.2215/CJN.02560220
115. Carney K, Cousins M. Does hydrochlorothiazide increase the incidence of skin, lip and oral cancer in a UK population? Evid Based Dent 2022; 23 (1): 38–9. DOI: 10.1038/s41432-022-0255-x
116. Eworuke E, Haug N, Bradley M et al. Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States. JNCI Cancer Spectr 2021; 5 (2): pkab009. DOI: 10.1093/jncics/pkab009
116. Rouette J, Yin H, Pottegård A et.al. Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer. Drug Saf 2021; 44 (2): 245–54. DOI: 10.1007/s40264-020-01015-1
117. de Macedo Andrade AC, Felix FA, França GM et al. Hydrochlorothiazide use is associated with the risk of cutaneous and lip squamous cell carcinoma: A systematic review and meta-analysis. Eur J Clin Pharmacol 2022; 78 (6): 919–30. DOI: 10.1007/s00228-022-03299-x
118. Shao SC, Lai CC, Chen YH et al. Associations of thiazide use with skin cancers: a systematic review and meta-analysis. BMC Med 2022; 20 (1): 228. DOI: 10.1186/s12916-022-02419-9
119. Habel LA, Achacoso N, Fireman B et.al. Hydrochlorothiazide and risk of melanoma subtypes. Pharmacoepidemiol Drug Saf 2021; 30 (10): 1396–401. DOI: 10.1002/pds.5266
120. Adalsteinsson JA, Muzumdar S, Waldman R et al. Association between hydrochlorothiazide and the risk of in situ and invasive squamous cell skin carcinoma and basal cell carcinoma: A population-based casecontrol study. J Am Acad Dermatol 2021; 84 (3): 669–75. DOI: 10.1016/j.jaad.2020.08.025
For citation:Trukhan D.I. Baboon syndrome or symmetric intertriginal and flexible exanthemas associated with medicines. Review of clinical cases. Clinical review for general practice. 2023; 4 (5): 63–70 (In Russ.). DOI: 10.47407/kr2023.4.5.00236
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.